A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

This study is testing OR502, a new antibody drug that targets a protein called LILRB2 on immune cells, to see if it can help the immune system better fight advanced solid cancers. The drug will be tested alone and in combination with other anti-cancer drugs in people whose cancer has progressed on prior treatments. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of carcinoma, sarcoma, or melanoma that has progressed to an advanced or metastatic stage - Your cancer has progressed on or you are intolerant to standard treatments - You have measurable disease on imaging - Your overall health and organ function are adequate **You may NOT be eligible if...** - You have had another invasive cancer in the past 2 years - You have active autoimmune disease requiring treatment - You have received certain prior immunotherapy treatments recently - You have brain metastases that are not stable - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.